Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A marker combination and its application in the preparation of colorectal cancer diagnostic reagents

A technology of diagnostic reagents and markers, applied in the field of biomedicine, can solve problems such as no significant improvement, and achieve high accuracy, improved survival rate, high sensitivity and specificity

Active Publication Date: 2020-07-28
THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Kuo et al. reported that the marker phospholipid scramblase 1 (PLSCR1) combined with CEA to diagnose colorectal cancer, after the combination, the sensitivity increased from 80% to 85%, without significant improvement (Y.Kuo et al., Identification of phospholipid scramblase1 as a biomarker and determination of its prognostic value for colorectal cancer. Molecular medicine; 17,41-47(2011)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A marker combination and its application in the preparation of colorectal cancer diagnostic reagents
  • A marker combination and its application in the preparation of colorectal cancer diagnostic reagents
  • A marker combination and its application in the preparation of colorectal cancer diagnostic reagents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Embodiment 1 sample source and analysis

[0091] A total of 87 patients (stages I, II, III, and IV) diagnosed with colorectal cancer in the Sixth Affiliated Hospital of Sun Yat-sen University from September 2018 to December 2018 were collected, all of whom were confirmed by imaging and pathological examination. All pathological results were obtained by tissue biopsy. The patient had no serious organ disease, and had not received chemotherapy, radiotherapy or surgery. A total of 90 cases were collected as controls from a healthy population at the same time. The inclusion criteria for healthy controls were that there were no obvious abnormalities in the results of blood routine and biochemical tests, and no infectious diseases such as hepatitis B. The basic information is shown in Table 2. All blood samples were collected using EDTA anticoagulant tubes. Plasma separation was completed within 6 hours at room temperature, centrifuged at 3000 rpm for 2 minutes, and the pla...

Embodiment 2

[0096] Embodiment 2 Tumor marker content determination method

[0097] The content of RANTES in the present invention adopts enzyme-linked immunosorbent assay (ELISA) detection, selects commercial kit RayBiotech Human RANTES ELISA Kit, Biotek Elx800 microplate reader 450nm, Biotek Elx50 washer, pipette, small centrifuge tube, Ionized water, Sigmaplot analysis software, etc. The contents of CEA, CA125 and CA199 were detected by chemiluminescent enzyme immunoassay (CLEIA) in Abbott I2000.

[0098] (1) Equilibrate the kit and samples to room temperature (18-25°C);

[0099] (2) The diluent is diluted 5 times with deionized water for later use;

[0100] (3) Plasma samples were diluted 40 times for later use;

[0101] (4) Standard product preparation: Centrifuge the small tube of the standard product, then add 400 μL of 1× diluent to the small tube of the standard product, and mix well to obtain a 50 ng / mL standard product stock solution; draw 40 μL of the standard product stock ...

Embodiment 3

[0114] Example 3 Tumor markers to the diagnostic efficacy test results of colorectal cancer

[0115] 1. Using CEA, CA125, CA199 and RANTES as tumor markers, the corresponding Youden index and cutoff values ​​obtained from the samples in Example 1 detected by the measurement method in Example 2 are shown in Table 3.

[0116] Table 3 Youden index maximum value and cutoff value corresponding to CEA, CA125, CA199, RANTES

[0117]

[0118] 2. Combined indicators to predict the diagnostic efficacy of CRC

[0119] CEA, CA125, CA199, and RANTES combined schemes to compare the diagnostic efficiency of colorectal cancer in the samples in Example 1. Wherein, the data are calculated for 87 colorectal cancer patients and 90 healthy controls in Example 1.

[0120] The ROC curve is obtained by Logistic regression, in which the independent variable is the corresponding index, and the dependent variable is the cancer status. The probability of each individual suffering from cancer can be ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of biological medicine, and relates to a marker combination, application thereof in preparing a diagnostic reagent for colorectal cancer and the diagnostic reagent or kit for the colorectal cancer. Markers RANTES and CEA in blood are combined, it is found that the marker combination is very high in degree of association with the colorectal cancer, the sensitivityof the marker combination can reach 98.9%, and the specificity is even up to 100%. For diagnosis of early colorectal cancer, the marker combination is high in sensitivity and specificity, and the sensitivity of the marker combination can be even up to 100%, which is very rare clinically, the marker combination can be used for early detection of the colorectal cancer, time is bought for a patient,the patient starts to be treated as early as possible, and the survival rate of the patient is increased.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a marker combination and its application in preparing a colorectal cancer diagnostic reagent and a colorectal tumor diagnostic reagent / kit. Background technique [0002] Global cancer statistics predict 18.1 million new cancer cases and 9.6 million deaths in 2018. Colorectal cancer (CRC) is a common malignant tumor of the digestive tract. The incidence and mortality of colorectal cancer in my country rank third among all malignant tumors, and the incidence is still rising. Studies have shown that screening individuals with colorectal cancer risk factors can lead to early diagnosis of cancer, reduce mortality, and even reduce the incidence of colorectal cancer by finding and removing adenomas. The United States began to promote early screening of colorectal cancer as early as the 1980s, and the 5-year survival rate of colorectal cancer patients in the United States has reached 90%, which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886C12Q2600/158G01N33/57419G01N33/57484
Inventor 刘焕亮张瀞丹谭会柳赵璐肖艳红胡素华钟硕贤徐重杨湘玲
Owner THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com